Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ASCO relevance

<< Previous

Bullboard Posts

Next >>

Comment by Geneman2004on Apr 30, 2023 12:58am

207 Views

Post# 35421353

RE:RE:RE:RE:RE:ASCO relevance

oops.....hold out for hundreds of dollars if there is an offer for $10?

I would not put any value on the fact that I am back posting. The company faces a binary event after many years of crickets......lots going on but crickets in terms of investing impact. I would want to discuss all of these topics. I think we enter a very interesting time but I certainly acknowledge that there are lots of risks and a complicated road forward. Everyone needs to keep their eyes open. Biotech has been very tough sledding for the last couple years and the tide needs to turn before we see the valuations of the past.

<< Previous

Bullboard Posts

Next >>

Soma Gold poised to extend profitable track record